IMNN

0.53555.22%
MH

Michael H. Tardugno

Executive Chairman

Mr. Michael H. Tardugno serves as Executive Chairman at Imunon, Inc. (formerly known as Celsion Corporation) since October 7, 2014 and served as its Chief Executive Officer and President since January 3, 2007 until July 18, 2022. Mr. Tardugno has an extensive experience in Pharmaceutical industry leadership. He served as Senior Vice President and General Manager of Mylan Laboratories Inc., since February 2005 until December 2006. From 1998 to 2005, he served as an Executive Vice President and a Founding Member of Management of Songbird Hearing, Inc., where he forged a number of significant agreements with major US and International Partners in the development and commercialization of the world's first disposable hearing aid. Mr. Tardugno served as a Senior Vice President of ConvaTec, a division of Bristol-Myers Squibb from 1996 to 1998 and its Vice President of Technology Development & Manufacturing of Bausch & Lomb from 1989 to 1995. He started his career with Abbott Laboratories holding positions in pharmaceutical operations, Principally as plant Manager for its Ross Laboratories Division nutritional business. From 1996 to 1998, he was Senior Vice President of Technical Operations worldwide for a division of Bristol-Myers Squibb. From 1977 to 1995, he held increasingly senior executive positions including Senior Vice President of Worldwide Technology Development with Bausch & Lomb and Abbott Laboratories. Mr. Tardugno has been a Director at Imunon, Inc. (formerly known as Celsion Corporation) since January 22, 2007. He served as a Director of Theranostics Health, LLC. Mr. Tardugno holds a B.S. in Biology and Chemistry minor from St. Bonaventure University and attended Program for Management Development from Harvard Business School.

Positions